Cargando…

Editorial: Novel Strategies for Cancer Immunotherapy: Targeting Immune-Mediated Suppressive Mechanisms

Detalles Bibliográficos
Autores principales:	Lafont, Virginie, Lucas, Sophie, Bonnefoy, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128245/ https://www.ncbi.nlm.nih.gov/pubmed/34012459 http://dx.doi.org/10.3389/fimmu.2021.691899

Ejemplares similares

Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy
por: Chabab, Ghita, et al.
Publicado: (2020)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II
por: Xu, Caili, et al.
Publicado: (2023)

Editorial: The immune escape mechanism and novel immunotherapeutic strategies of leukemia
por: Yu, Kang, et al.
Publicado: (2023)

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy
por: Feron, Olivier, et al.
Publicado: (2023)

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response
por: Lafont, Virginie, et al.
Publicado: (2014)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
por: Shi, Tao, et al.
Publicado: (2023)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
por: Dong, Yan, et al.
Publicado: (2021)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Editorial: Extracellular traps in cancer immunity and immunotherapy
por: Rahat, Michal A., et al.
Publicado: (2023)

Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023)

Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2023)

Editorial: New insights in sepsis pathogenesis and renal dysfunction: Immune mechanisms and novel management strategies
por: Stasi, Alessandra, et al.
Publicado: (2023)

Editorial: Rare immune-mediated diseases- novel insights into underlying mechanisms and therapeutic approaches
por: Shamriz, Oded, et al.
Publicado: (2023)

Editorial: Heterologous Immunity: Implications and Applications in Vaccines and Immunotherapies
por: Singh, Shakti, et al.
Publicado: (2020)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
por: Martin, Francisco, et al.
Publicado: (2022)

Editorial: Non-coding RNA in immunotherapies and immune regulation
por: Kaeffer, Bertrand, et al.
Publicado: (2022)

Editorial: Emerging talents in cancer immunity and immunotherapy: 2022
por: Maeurer, Markus
Publicado: (2023)

Editorial: Rising stars in cancer immunity and immunotherapy 2022
por: Goyvaerts, Cleo, et al.
Publicado: (2023)

Editorial: Immune Outposts on the Inflammatory Frontier: Tertiary Lymphoid Structures as Targets for Immunotherapy of Cancer and Autoimmunity
por: Silina, Karina, et al.
Publicado: (2019)

Editorial: Dual role of inflammatory mediators in cancer immunotherapy
por: Wang, Xiaoli, et al.
Publicado: (2023)

Editorial: Mechanisms and strategies of unconventional antibody diversification for greater immune adaptability
por: Dimitrov, Jordan D., et al.
Publicado: (2023)

Editorial: Macrophage immunity and metabolism in cancer: Novel diagnostic and therapeutic strategies
por: Leavenworth, Jianmei W., et al.
Publicado: (2022)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy
por: Dai, Xiangpeng, et al.
Publicado: (2022)

Editorial: The role of multi-omics variants in tumor immunity and immunotherapy
por: Chen, Shuang, et al.
Publicado: (2022)

Editorial: The challenge of immunity evaluation and immunotherapy in gynecologic and urologic oncology
por: Tan, Ruirong, et al.
Publicado: (2023)

Editorial: Updates on toll-like receptors in cancer immunity and immunotherapy
por: Hoden, Bettina, et al.
Publicado: (2023)

Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
por: Su, Yang, et al.
Publicado: (2023)

Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer
por: Li, Tianhang, et al.
Publicado: (2022)

Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume I
por: Di, Xiang-jie, et al.
Publicado: (2023)

Editorial: Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy
por: Plantinga, Maud, et al.
Publicado: (2022)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer
por: Cifaldi, Loredana, et al.
Publicado: (2020)

Editorial: The Spectrum of Lymphoid Subsets in Allergic Diseases: Immune Regulation and Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2022)

Editorial: The relationship between COVID-19 severity and cancer immunity and immunotherapy
por: Nunès, Jacques A., et al.
Publicado: (2023)

Editorial: Melanocortins and melanocortin receptors in the regulation of inflammation: mechanisms and novel therapeutic strategies
por: Rinne, Petteri, et al.
Publicado: (2023)

Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies
por: Bianchi, Elisabetta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1p7f0en7tr9ngtoft42fp3kiii